News of Note—Bavarian Nordic, BiondVax and more

In this week's News of Note, BiondVax announced an NIH-supported phase 2 study of its universal flu vaccine candidate.

Here is some other vaccine news of note for the week.

> The U.S. government awarded Bavarian Nordic an option worth $37 million to support phase 3 testing on the freeze-dried version of smallpox vaccine Imvamune. Release

> BiondVax and the U.S. National Institutes of Health teamed up to work on a phase 2 study of universal flu shot candidate M-001. Release

> Russia's top vaccine producer, Natsimbio, announced a $100 million investment for a new manufacturing plant. The Pharma Letter story